Advances in hematologic stem cell transplant: An update for oral health care providers

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 107, Issue 3, 2009, Pages 301-312

  Epstein, Joel B ^a   Raber Drulacher, Judith E ^b   Wilkins, Affi ^a   Chavarria, Maria Gabriella ^a   Myint, Han ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; DENTAL CARE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MUCOSA INFLAMMATION; NEOPLASM; ORAL BLEEDING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STOMATITIS; TASTE DISORDER; XEROSTOMIA;

BONE MARROW TRANSPLANTATION; DENTAL CARE FOR CHRONICALLY ILL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; LIVING DONORS; LYMPHOCYTE TRANSFUSION; MUCOSITIS; NEOPLASMS; ORAL HEMORRHAGE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STOMATITIS; TASTE DISORDERS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; XEROSTOMIA;

EID: 59649130301     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2008.12.006     Document Type: Article

References (84)

1. Jacobson L.O., Simmons E.L., Marks E.K., Robson M.J., Bethard W.F., and Gaston E.O. The role of the spleen in radiation injury and recovery. J Lab Clin Med 35 (1950) 746-770
2. Thomas E.D., Lochte Jr. H.L., Lu W.C., and Ferrebee J.W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257 (1957) 491-496
3. Copelan E.A. Hematopoietic stem cell transplantation. N Engl J Med 354 (2006) 1813-1826
4. Barnes D.W., and Loutit J.F. Treatment of murine leukaemia with x-rays and homologous marrow II. Br J Haematol 3 (1957) 241-252
5. Dausset J. Iso-leuco-anticorps. Acta Hematol 20 (1958) 156-166
6. Jansen J. Jon van Rood: Pioneer at the crossroad of human leukocyte antigens and transplantation. Trans Med Rev 21 (2006) 159-163
7. Thomas E.D., Fefer A., Buckner C.D., and Storb R. Current status of bone marrow transplantation for aplastic anemia and acute leukemia. Blood 49 (1979) 671-681
8. Appelbaum F.R. The current status of hematopoietic stem cell transplantation. Ann Rev Med 54 (2003) 491-512
9. Riley R.S., Idowo M., Chesney A., Zhao S., McCarthy J., Lamb L.S., et al. Hematologic aspects of myeloablative therapy and bone marrow transplantation. J Clin Lab Anal 19 (2005) 47-79
10. Elfenbein G.J., and Sackstein R. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady state marrow. Exp Hematol 32 (2004) 327-339
11. Beyer J., Schella N., Zingsem J., Strohscheer I., Schwaner I., Oettle H., et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 13 (1995) 1328-1335
12. Storek J., Dawson M.A., Storer B., Stevens-Ayers T., Maloney D.G., Marr K.A., et al. Immune reconstitution after allogeneic marrow transplantation: does the source of hematopoietic stem cells matter?. Blood 98 (2001) 2900-2908
13. Flowers M.E., Parker P.M., Johnston L.J., Matos A.V., Storer B., Bensinger W.I., et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long term follow up of a randomized trial. Blood 100 (2002) 415-419
14. Cohen Y., and Nagler A. Umbilical cord blood transplantation-how, when and for whom?. Blood Rev 18 (2004) 167-179
15. Chao N.J., Emerson S.G., and Weinberg K.I. Stem cell transplantation (cord blood transplants). Hematology (2004) 357-371
16. Majhail N.S., Brunstein C.G., and Wagner J.E. Double umbilical cord blood transplantation. Curr Opin Immunol 18 (2006) 571-575
17. Dean M., Fojo T., and Bates S. Tumor stem cells and drug resistance. Nat Rev Cancer 5 (2005) 275-284
18. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol 8 (1996) 75-88
19. Bacigalupo A. Second EBMT workshop on reduced intensity allogeneic hematopoietic cell transplant (RI-HSCT). Bone Marrow Transplant 29 (2002) 191-195
20. Barrett A.J., and Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 20 (2006) 1661-1672
21. Baron F., and Storb R. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Curr Opin Hematol 14 (2007) 145-151
22. Shapira M.Y., Tsirigotis P., Resnick I.B., Or R., Abdul Hai A., and Slavin S. Allogeneic hematopoietic stem cell transplantation in the elderly. Crit Rev Oncol Hematol 64 (2007) 49-63
23. Mathé G. Lessons from past experience in cancer immunotherapy and their application to cancer and AIDS treatment and prophylaxis. Biomed Pharmocother 8 (1989) 551-561
24. Luznik L., and Fuchs E.J. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. J Cancer Control 9 (2002) 123-137
25. Marijt E., Wafelman A., van der Hoorn M., van Bergen C., Bongaerts R., van Luxemburg-Heijs S., et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica 92 (2007) 72-80
26. Kennedy-Nasser A.A., and Bollard C.M. T Cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI?. Bone Marrow Transplant 40 (2007) 93-104
27. Bellm L.A., Epstein J.B., Rose-Ped A., Martin P., and Fuchs H.J. Patient reports of complications of bone marrow transplantation. Support Care Cancer 8 (2000) 33-39
28. Sonis S.T., Oster G., Fuchs H., Bellm L., Bradford W.Z., and Edelsberg J. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19 (2001) 2201-2205
29. Elting L.S., Avritscher E.B., Cooksley C.D., Cardenas-Turanzas M., Garden A.S., and Chamber M.S. Psychosocial and economic impact of cancer. Dent Clin North Am 52 (2008) 231-252
30. Sonis S.T., Elting L.S., Keefe D., Peterson D.E., Schubert M.M., Hauer-Jensen M., et al., Mucositis Study Section of the Multinational Association for Supportive Care in Cancer, International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 Suppl (2004) 1995-2025
31. Wardley A.M., Jayson G.C., Swindell R., Morgenstern G.R., Chang J., Bloor R., et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and hematopoietic progenitor treatment. Br J Hematol 110 (2000) 292-299
32. Robien K., Schubert M.M., Bruemmer B., Lloid M.E., Potter J.D., and Ulrich C. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 22 (2004) 1268-1275
33. Cutler C., Li S., Kim H.T., Laglenne P., Hoffmeister L., et al. Mucositis after allogeneic hematopoietic stem cell transplantation; a cohort study of methotrexate and nonmethotrexate containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 11 (2005) 383-388
34. Vela-Ojeda J., Garcia-Ruiz Esparza M.A., Tripp-Villanueva F., Ayala-Sanchez M., Delgrado-Lamas J.L., Garces-Ruiz O., et al. Allogeneic peripheral blood stem cell transplantation using reduced-intensity versus myeloablative conditioning regimens for the treatment of leukemia. Stem Cells Devel 13 (2004) 571-578
35. Holmberg L.A. Blood and marrow transplantation. In: Wingard J.R., and Bowden R.A. (Eds). Management of infection in oncology patients (2003), Martin Dunitz, London, UK 37-49
36. Greenberg M.A., Cohen S.G., McKitrick J.C., and Cassileth P.A. The oral flora as a source of septicemia in patients with acute leukemia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 53 (1982) 32-36
37. Heimdahl A., Mattson T., Dahllöf G., Lönnquist B., and Ringden O. The oral cavity as a portal of entry for early infections in patients treated with bone marrow transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 68 (1989) 711-716
38. Baquiro F., Fernandez J., Dronda F., Erice A., Perz de Oteiza J., Requira J.A., and Reig M. Capnophilic and anaerobic bacteremia in neutropenic patients: an oral source. Rev Infect Dis 2 Suppl 2 (1990) S157-S160
39. Laine P.O., Lindqvist J.C., Pyrhönen S.O., Strand-Pettinen I.M., Teerenhovi L.M., and Meurman J.H. Oral infection as a reason for febrile episodes in lymphoma patients receiving cytostatic drugs. Eur J Cancer B Oral Oncol 28B (1992) 103-107
40. Ruescher T.J., Sodeifi A., Scrivani S.J., Kaban L.B., and Sonis S.T. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 82 (1998) 2275-2281
41. Costa S.F., Micelli M.H., and Anaissie E.J. Mucosa or skin as a source of coagulase-negative staphylococcal bacteraemia?. Lancet Infect Dis 4 (2004) 278-286
42. Epstein J.B., and Chow A.W. Oral complication associated with immunosuppression and cancer therapies. Infect Dis Clin North Am 13 (1999) 901-923
43. Raber-Durlacher J.E., Epstein J.B., Raber J., van Dissel J.T., van Winkelhoff A.J., Guiot H.F., and van der Velden U. Periodontal infection in cancer patients treated with high-dose chemotherapy. Support Care Cancer 10 (2002) 466-473
44. Wandt H., Frank M., Ehnininger G., Schneider C., Brack N., Daoud A., et al. Safety and cost effectiveness of a 10 × 109/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91 (1998) 3601-3606
45. In: Ferrara J.M.L., Deeg H.J., and Burakoff S.J. (Eds). Graft-vs-host disease. 2nd ed. (1997), Marcel Dekker, New York 525-559
46. Deeg J.H., and Antin J.H. The clinical spectrum of acute graft-versus-host disease. Semin Hematol 43 (2006) 24-31
47. Filipovich A.H., Weisdorf D., Pavletic S., Socie G., Wingard J.R., Lee S.J., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 12 (2005) 945-956
48. Woo S.B., Lee S.J., and Schubert M.M. Graft-vs-host disease. Crit Rev Oral Biol Med 8 (1997) 201-216
49. Ferrara J.L., and Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 43 (2006) 3-10
50. Schubert M.M., and Correa M.E. Oral graft-versus-host disease. Dent Clin North Am 52 (2008) 79-109
51. Pavletic S.Z., Lee S.J., Socie G., and Vogelsang G. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant 38 (2006) 645-651
52. Baird K., and Pavletic S.Z. Graft versus host disease. Curr Opin Hematol 13 (2006) 226-235
53. Schultz K.R., Miklos D.B., Fowler D., Cooke K., Shizuru J., Zorn E., et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease III. Biomarker Working Group report. Biol Blood Marrow Transplant 12 (2006) 126-137
54. Couriel D., Carpenter P.A., Cutler C., Bolanos-Meade J., Treister N.S., Gea-Banacloche J., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease V: Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant 12 (2006) 375-396
55. Baron F., Little M.T., and Storb R. Kinetics of engraftment following allogeneic hematopoietic stem cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev 19 (2005) 153-164
56. Barrett J. Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment. Curr Opin Immunol 18 (2006) 592-598
57. Elad S., Shapira M.Y., McNeal S., Or R., Garfunkel A.A., Hirschhorn A., et al. Oral effects of nonmyeloablative stem cell transplantation: a prospective observational study. Quintessence Int 39 (2008) 673-678
58. Larsen J., Nordstöm G., Ljungman P., and Gardulf A. Factors associated with poor general health after stem-cell transplantation. Support Care Cancer 15 (2007) 849-857
59. Nieuw van Amerongen A., and Veerman E.C. Saliva-the defender in the oral cavity. Oral Dis 8 (2002) 12-22
60. Epstein J.B., Tsang A.H., Warkentin D., and Ship J.A. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94 (2002) 39-44
61. Imanguli M.M., Atkinson J., Harvey K.E., Hoehn G.T., Ryu O., Wu T., et al. Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Exp Hematol 35 (2007) 184-192
62. Marinone M.G., Rizzoni D., Ferremi P., Rossi G., Izzi T., and Brusotti C. Late taste disorders in bone marrow transplantation: clinical evaluation with taste solutions in autologous and allogeneic bone marrow recipients. Haematologica 76 (1991) 519-522
63. Adès L., Guardiola P., and Socié P. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insights and current problems. Blood Rev 16 (2002) 135-146
64. Elad S., Meyerowitz C., Shapira M.Y., Glick M., Bitan M., and Amir G. Oral posttransplantation lymphoproliferative disorder: an uncommon site for an uncommon disorder. Oral Surg Oral Pathol Oral Radiol Endod 105 (2008) 59-64
65. Curtis R.E., Rowlings P.A., Deeg H.J., Shriner D.A., Socié G., Travis L.B., et al. Solid cancers after bone marrow transplantation. N Engl J Med 336 (1997) 897-1004
66. Demarosi F., Lodi G., Carrassi A., Soligo D., and Sardella A. Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol 41 (2005) 865-877
67. Schulte C.M., and Beelen D.W. Avascular osteonecrosis after allogeneic hematopoietic stem cell transplantation: diagnosis and gender matter. Transplantation 78 (2004) 1055-1063
68. Migliorati C.A., Casiglia J., Epstein J.B., Jacobsen P.L., Siegel M.A., and Woo S.-B. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 136 (2005) 1658-1668
69. National Cancer Institute. Oral complication of chemotherapy and head/neck radiation PDQ. Bethesda, MD: National Institutes of Health. http://www. nci.nih.gov./cancerinfo/pdq/supportive care/oral complications/healthprofessional Accessed Sept 10, 2008
70. Westbrook S.D., Paunovich E.D., and Freytes C.O. Adult hemopoietic stem cell transplantation. J Am Dent Assoc 134 (2003) 1224-1231
71. Elad S., Thierer T., Bitan M., Shapira M.Y., and Meyerowitz C.A. Decision analysis: the dental management of patients prior to hematology cytotoxic therapy or hematopoietic stem cell transplantation. Oral Oncol 44 (2008) 37-42
72. Barker G.J. Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Support Care Cancer 7 (1999) 17-20
73. Keefe D.M., Schubert M.M., Elting L.S., Sonis S.T., Epstein J.B., Raber-Durlacher J.E., et al. Mucositis Study Section, Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109 (2007) 820-831
74. Spielberger R., Stiff P., Bensinger W., Gentile T., Weisdorf D., Kewalramani T., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 (2004) 2590-2598
75. Galbraith L.K., Bailey D., Kelly L., Rehn K., Spear S., Steinle C., et al. Treatment for alteration in oral mucosa related to chemotherapy. Pediatr Nurs 17 (1991) 233-236
76. Epstein J.B., Hancock P.J., and Nantel S. Oral candidiasis in hematopoietic cell transplantation patients: an outcome-based analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96 (2003) 154-163
77. Epstein J.B., Truelove E.L., Hanson-Huggins K., Mancl L.A., Chen A., Press O.W., et al. Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy. Support Care Cancer 12 (2004) 517-525
78. Epstein J.B., Phillips N., Parry J., Epstein M.S., Nevill T., and Stevenson-Moore P. Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 30 (2002) 785-792
79. Schubert M.M., Peterson D.E., and Lloid M.E. Oral complications. In: Thomas E.D., Blume K.G., and Forman S.J. (Eds). Hematopoietic cell transplantation. 2nd ed. (1999), Blackwell Science, Malden (MA) 751-763
80. Epstein J.B., Epstein J.D., Epstein M.S., Oien H., and Truelove E.L. Management of pain in cancer patients with oral mucositis: follow-up of multiple doses of doxepin oral rinse. J Pain Symptom Manage 33 (2007) 111-114
81. Atkinson J.C., Grisius M., and Massey W. Salivary hypofunction and xerostomia. Dent Clin North Am 49; (2005) 309-326
82. Dahllöf G. Craniofacial growth in children treated for malignant diseases. Acta Odont Scand 56 (1998) 378-382
83. Uderzo C., Fraschini D., Balduzzi A., Galimberti S., Arrigo C., Biagi E., et al. Long-term effects of bone marrow transplantation on dental status in children with leukaemia. Bone Marrow Transplant 20 (1997) 865-869
84. Hölttä P., Hovi L., Saarinen-Pihkala U.M., Peltola J., and Alaluusua S. Disturbed root development of permanent teeth after pediatric stem cell transplantation. Dental root development after SCT. Cancer 103 (2005) 1484-1493